Genetic testing services provider Prenetics, a spinout of City University of Hong Kong, will hold a reverse merger at a $1.25bn valuation.

Based on research at Drexel University, Context Therapeutics is seeking to raise up to $21m in an initial public offering on Nasdaq.

Dundee spinout Exscientia is continuing a busy fundraising year with a filing for an IPO in the US and a $35m concurrent private placement.

The Adimab and GV-backed covid-19 antibody treatment developer has floated on Nasdaq at a $1.84bn valuation, about a year after it was founded.

The Ant Group, Aucfan, Emtek, Gree, Microsoft and Naver-backed digital marketplace owner’s shares on IDX jumped 25% on the first day of trading.

The multi-corporate-backed biologic pill developer has listed on the Nasdaq Global Market, pricing the shares below their range.

The corporate-backed consumer credit platform operator will get a Nasdaq listing from the transaction, which will include $120m in Pipe financing co-led by Palantir Technologies.

UW's vaccine development company has listed on Nasdaq, with its shares rising on the first day of trading.

The GV-backed cardiovascular therapeutics company has priced an upsized offering on Nasdaq, with the shares closing just marginally higher on the first day.

Mitsui and Nan Fung are among the backers celebrating Rallybio’s flotation on the Nasdaq Global Select Market following an $80.6m offering.